Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
RegenX
AddedFeb 18, 2024
UpdatedJun 18, 2026
RegenX

RegenX

Angel

RegenX, a Massachusetts-based medical organization, offers an injectable system to enhance tendon and ligament healing.

HQ
Burlington, MA, US
Founded
2017
Overview
Compare
Fundraising
Employees

RegenX, a Massachusetts-based medical organization, focuses on improving the quality of life and reducing healthcare costs related to tendon and ligament injuries. They offer an innovative injectable repair system designed to accelerate healing time and enhance repair quality.

RegenX has made significant strides in the medical field by addressing the slow and challenging healing process of tendon and ligament injuries. Their advancements have the potential to transform patient outcomes and reduce long-term healthcare expenses.

RegenX - Similar Companies

BioRegenx logo

BioRegenx

bioregenx.com

RegeneRx Biopharmaceuticals logo

RegeneRx Biopharmaceuticals

Tissue Regeneration logo

Tissue Regeneration

RegenX Science logo

RegenX Science

regenxscience.com

Regenemed logo

Regenemed

regenemed.com

Regennova logo

Regennova

regennova.com

Endogena Therapeutics logo

Endogena Therapeutics

ReLive logo

ReLive

relivebio.com

Juvent - Regenerative Technologies logo

Juvent - Regenerative Technologies

juvent.com

Sofregen Medical logo

Sofregen Medical

Renerva logo

Renerva

renerva.com

Regenxbio logo

Regenxbio

regenxbio.com

Lynch Regenerative Medicine logo

Lynch Regenerative Medicine

Exogenesis logo

Exogenesis

Regenacy Pharmaceuticals logo

Regenacy Pharmaceuticals

RegenX - Quick Facts

Who are RegenX's competitors?

Companies similar to RegenX include BioRegenx, RegeneRx Biopharmaceuticals, Tissue Regeneration and RegenX Science.

When was RegenX founded?

RegenX was founded in 2017.

Where is RegenX's headquarters located?

RegenX's headquarters is located in Burlington, MA, US.

When was RegenX's last funding round?

RegenX's most recent funding round was for $255.9k (USD) in September 2020.

How much has RegenX raised to-date?

As of Sep 14, 2020, RegenX has raised a total of $255.9k (USD).

How many employees does RegenX have?

RegenX has 5 employees as of Feb 4, 2024.

RegenX - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified